Advancements in MS Treatments 2025 ECTRIMS

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to Wish List failed.

Please try again later

Remove from Wish List failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Advancements in MS Treatments 2025 ECTRIMS

Listen for free

View show details

About this listen

Join Dr. Agne Straukiene, a neurologist specialising in Multiple Sclerosis, as she unveils groundbreaking treatments discussed at the ECTRIMS 2025 conference. Discover how BTK inhibitors like #Tolebrutinib, #Evobrutinib, #Orelabrutinib, #Remibrutinib, and #Fenebrutinib could revolutionize MS care by targeting both B cells and brain cells to reduce inflammation and progression. Learn about #Frexalimab's novel mechanism and promising trial results, the potential of combining #Clemastine and #Metformin for myelin repair, and remarkable long-term outcomes of autologous haematopoietic stem cell transplantation. Explore the exciting advent of #CART cell therapy poised to change the future of MS treatment.

00:00 Introduction to MS and ECTRIMS 2025
00:24 Understanding BTK Inhibitors
01:05 Key BTK Inhibitors Discussed
04:00 Frexalimab: A New Approach
05:09 Combination Therapies: Clemastine and Metformin
06:05 Stem Cell Therapy: Long-term Outcomes
07:43 CAR T Cell Therapy: Cutting-edge Treatment
08:57 Conclusion and Future Outlook

Become a supporter of this podcast: https://www.spreaker.com/podcast/beewellwithms-podcast-by-dr-agne-straukiene--5762905/support.

This episode includes AI-generated content.

No reviews yet